DO ELITE CONTROLLERS REQUIRE ART FOR SECONDARY BENEFITS?

Clinical Infectious Diseases, May 2019

There is an ongoing debate in the literature about whether elite controllers require antiretroviral therapy (ART) for secondary benefits, including control for low-level viral replication and reduction of inflammation. ACTG A5308 attempted to resolve this debate by looking at the effect of ART on virologic suppression, the viral reservoir, immune activation, and quality of life in a group of elite controllers enrolled in the ACTG.

https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciz442/5498857?searchresult=1